SecurityWLH / Lyon William Homes (552074700)
IndustryOperative Builders
Common Shares Outstanding33,202,209 shares (as of 2018-03-31)
Total Insiders18
Total Directors8
Total Officers7

Stock Insider Trading (from SEC Form 4)

WLH / Lyon William Homes Insider Trades

Lyon William Homes insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

WLH / Lyon William Homes insiders include ZAIST MATTHEW R, LILJESTROM JASON R, NIEMANN MATTHEW R, Hunt Gary H, Luxor Capital Partners, LP, GMT CAPITAL CORP, ROBINSON RICHARD S, and DOYLE BRIAN W, SEVERN COLIN T, SCHELL LYNN CARLSON, Luxor Wavefront, LP, LCG HOLDINGS LLC, LYON WILLIAM H, Paulson Property Management II LLC LYON WILLIAM, HARRISON THOMAS F, Ammerman Douglas K, Luxor Capital Group, LP, .

Insider Roster

Insider Dir Off 10% Shares Owned
GMT CAPITAL CORP 10% Owner
X 3,484,627
DOYLE BRIAN W EVP & COO
X 166,856
SEVERN COLIN T SVP & Chief Financial Officer
X 97,207
LILJESTROM JASON R SVP Gen. Counsel & Secretary
X 45,669
ZAIST MATTHEW R President & CEO, Director
X X 415,938
LYON WILLIAM H Executive Chairman, Director, 10% Owner
X X X 299,649
NIEMANN MATTHEW R Director
X 43,963
Hunt Gary H Director
X 34,446
HARRISON THOMAS F Director
X 21,314
SCHELL LYNN CARLSON Director
X 57,644
Ammerman Douglas K Director
X 50,246
Paulson Property Management II LLC 10% Owner
X 0
LYON WILLIAM Executive Chairman, Director
X X
Luxor Capital Partners, LP 10% Owner
Luxor Capital Group, LP 10% Owner
LCG HOLDINGS LLC 10% Owner
Luxor Wavefront, LP 10% Owner
X
ROBINSON RICHARD S SVP of Finance & Acquisition
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-07-10 4 GMT CAPITAL CORP S D 23.75 10,790 3,484,627 82,759,891
2018-04-04 4 DOYLE BRIAN W S X D 28.0191 -15,596 166,856 4,675,155
2018-03-01 4 LYON WILLIAM H F D 25.28 -43,961 299,649
2018-03-01 4 ZAIST MATTHEW R F D 25.28 -50,050 415,938
2018-03-01 4 DOYLE BRIAN W F D 25.28 -18,681 182,452
2018-03-01 4 LILJESTROM JASON R F D 25.28 -5,389 45,669
2018-03-01 4 SEVERN COLIN T F D 25.28 -13,756 97,207
2018-02-22 4 DOYLE BRIAN W A D 12,714 201,133
2018-02-22 4 LILJESTROM JASON R A D 5,722 51,058
2018-02-22 4 LYON WILLIAM H A D 15,891 343,610
2018-02-22 4 SEVERN COLIN T A D 8,581 110,963
2018-02-22 4 ZAIST MATTHEW R A D 27,334 465,988
2018-02-22 4 Ammerman Douglas K A D 4,195 50,246
2018-02-22 4 SCHELL LYNN CARLSON A D 4,195 57,644
2018-02-22 4 HARRISON THOMAS F A D 4,195 21,314
2018-02-22 4 Hunt Gary H A D 5,148 34,446
2018-02-22 4 NIEMANN MATTHEW R A D 4,195 43,963
2018-02-15 4 DOYLE BRIAN W A D 48,650 188,419
2018-02-15 4 LILJESTROM JASON R A D 22,702 45,336
2018-02-15 4 LYON WILLIAM H A D 111,848 327,719
2018-02-15 4 SEVERN COLIN T A D 44,219 102,382
2018-02-15 4 ZAIST MATTHEW R A D 137,251 438,654
2018-01-29 4 GMT CAPITAL CORP S D 29.23 -34,300 3,495,417 102,171,039
2018-01-22 4 GMT CAPITAL CORP S D 32.13 -41,600 3,529,717 113,409,807
2018-01-16 4 GMT CAPITAL CORP S D 31.76 -44,700 3,571,317 113,425,028
2018-01-05 4 GMT CAPITAL CORP S D 30.99 -31,200 3,616,017 112,060,367
2018-01-02 4 GMT CAPITAL CORP S D 29.18 -31,200 3,647,217 106,425,792
2017-12-21 4 GMT CAPITAL CORP S D 28.38 -6,049 3,678,417 104,393,474
2017-12-18 4 GMT CAPITAL CORP S D 28.51 -11,620 3,684,466 105,044,126
2017-12-18 4 GMT CAPITAL CORP S D 29.03 -23,931 3,696,086 107,297,377
2017-12-13 4 GMT CAPITAL CORP S D 28.36 -5,100 3,720,017 105,499,682
2017-12-12 4 GMT CAPITAL CORP S D 28.73 -6,493 3,725,117 107,022,611
2017-12-11 4 GMT CAPITAL CORP S D 28.85 -19,607 3,731,610 107,656,948
2017-11-28 4 Hunt Gary H S D 29.3344 -2,500 29,298 859,439
2017-11-28 4 SEVERN COLIN T S D 29.264 -7,500 58,163 1,702,082
2017-11-17 4 ZAIST MATTHEW R By LLC S I 28.8289 -25,000 301,403 8,689,117
2017-09-18 4 Paulson Property Management II LLC See S I 23.81 -3,322,666 0
2017-09-11 4 GMT CAPITAL CORP S D 24.35 -41,600 3,751,217 91,342,134
2017-08-25 4 Hunt Gary H S D 22.8705 -8,500 31,798 727,236
2017-08-08 4 GMT CAPITAL CORP S D 23.09 -36,550 3,792,817 87,576,145
2017-08-07 4 GMT CAPITAL CORP S D 22.7 -15,450 3,829,367 86,926,631
2017-08-01 4 GMT CAPITAL CORP S D 22.74 -10,563 3,844,817 87,431,139
2017-07-31 4 GMT CAPITAL CORP S D 22.74 -10,237 3,855,380 87,671,341
2017-07-26 4 GMT CAPITAL CORP S D 23.38 -1,700 3,865,617 90,378,125
2017-07-25 4 GMT CAPITAL CORP S D 23.41 -34,959 3,867,317 90,533,891
2017-07-24 4 GMT CAPITAL CORP S D 23.29 -15,341 3,902,276 90,884,008
2017-07-19 4 GMT CAPITAL CORP S D 23.58 -16,422 3,917,617 92,377,409
2017-07-18 4 GMT CAPITAL CORP S D 23.37 -14,178 3,934,039 91,938,491
2017-07-17 4 GMT CAPITAL CORP S D 23.87 -16,200 3,948,217 94,243,940
2017-07-10 4 GMT CAPITAL CORP S D 23.86 -52,000 3,964,417 94,590,990
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

The Zacks Analyst Blog Highlights: Kforce, Burlington Stores, Brookline Bancorp, Federated National Holding and Salem Media Group

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Kforce Inc. (KFRC - Free Report) , Burlington Stores, Inc. (BURL - Free Report) , Brookline Bancorp, Inc. (BRKL - Free Report) , Federated National Holding Company (FNHC - Free Report) and Salem Media Group, Inc. (55-0)

Anadarko Petroleum, Symantec and Palo Alto Networks highlighted as Zacks Bull and Bear of the Day

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks Equity Research highlights Anadarko Petroleum (APC - Free Report) as the Bull of the Day, Symantec (SYMC - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Palo Alto Networks (PANW - Free Report) . (85-0)

The Zacks Analyst Blog Highlights: Visa, Medtronic, Salesforce, Dollar General and Martin Marietta

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Visa (V - Free Report) , Medtronic (MDT - Free Report) , Salesforce CRM, Dollar General (DG - Free Report) and Martin Marietta (MLM - Free Report) . (49-0)

The Zacks Analyst Blog Highlights: Zebra Technologies, Anhui Conch Cement and Graco

2018-06-05 zacks
Chicago, IL – June 5, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Zebra Technologies (ZBRA - Free Report) , Anhui Conch Cement (AHCHY - Free Report) and Graco (GGG - Free Report) . (48-0)

Zacks Industry Outlook Highlights: Lennar, M/I Homes and William Lyon Homes

2018-06-04 zacks
Chicago, IL – June 4, 2018 – Today, Zacks Equity Research discusses the Industry: Housing, Part 2, including Lennar (LEN - Free Report) , M/I Homes, Inc. (MHO - Free Report) and William Lyon Homes (WLH - Free Report) . (52-0)